Nabi Biopharma - Comparative Multiple Analysis

Nabi Biopharma (Comparative Multiple Analysis)


Notes on the Comparative Multiple Analysis of Nabi Biopharma

WikiWealth compares Nabi Biopharma's revenue, EBITDA, and EBIT multiples to their peers in order to determine the appropriate fair valuation. Click in the top right corner to experiment with Nabi Biopharma's comparative analysis.

Notes from the analysis:

1. WikiWealth uses quantitative measures to determine the multiple range for Nabi Biopharma.
2. Free cash flow to the firm (FCF) multiple is free cash flow to equity holders plus interest owed to Nabi Biopharma's debt holders.
3. Multiples incorporate benefits due to economies of scale; WikiWealth compares absolute enterprise value multiples to competitor's multiples.
4. WikiWealth excludes outliers when calculating individual company multiples.

Helpful Information for Nabi Biopharma's Analysis

How does this work? The Comparative Investment Analysis determines the value of Nabi Biopharma by comparing Nabi Biopharma financial ratios, prices, growth rates, margins, etc. to those of relevant peer groups.

Value Investing Importance? This method is widely used by investment professionals to determine the correct price of investments, especially initial public offerings (IPOs). It is one element of WikiWealth's three Wall Street approaches used to determine the correct fair value of Nabi Biopharma.

See the Nabi Biopharma cash flow (DCF) analysis for a completely different approach that's popular on Wall Street for determining the value of an investment in Nabi Biopharma.

Also, see the Nabi Biopharma's buffett intrinsic valuation analysis for WikiWealth's attempt to replicate the investing formula's used by Warren Buffett and Nabi Biopharma's valuation conclusion for a quick summary.